https://www.selleckchem.com/products/cp-43.html
Therapeutic approaches that modulate autophagy are a novel future direction for cancer drug development that may help to prevent issues with disease progression and overcome drug resistance. The purpose of this study was to design and manufacture CD19 chimeric antigen receptor (CAR)-modified T cells for clinical use in Thailand, as a model for how this technology can be directly applied at individual institutions treating high-risk leukemia patients. We constructed second-generation CAR T cells expressing CD19 scFV-CD28-CD3ζ with differen